|
Complainant part is expected to be returned for manufacturer review/investigation, but has yet to be received.The investigation could not be completed; no conclusion could be drawn, as no product was received.Based on the information available, it has been determined that no corrective and/or preventative action is proposed.This complaint will be accounted for and monitored via post market surveillance activities.If additional information is made available, the investigation will be updated as applicable.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.H3, h4, h6: part number: hl2ma, bme lot number: bhl170576, manufacturing date or release to warehouse date: 26 oct 2017, place of manufacture: biomedical enterprises, san antonio, tx, lot expiration date: 24 aug 2022.The pre-deployment hl2 complaint event is a known issue for hl2 implant kits manufactured before january 2018.Relevant actions have been taken.Review of the device history record also identified no relevant nonconformances.A visual review of complaint product photos titled ¿(b)(4) ¿ pictures from received part¿ attached to pi-(b)(4) was performed to determine the failure mode of this complaint.Review identified that plastic the inserter broke prematurely releasing the implant-tab assembly confirming the complaint condition.Performed 15 oct, 2019.This failure mode is a known issue and relevant actions have been taken.No manufacturing related issue was identified and/or confirmed, therefore review to the specific prm and prm line is not required.The potential impact of the design in the complaint condition has already been addressed.No new product design issues or discrepancies were observed that may have contributed to the complaint condition.Additional monitoring for any potential safety signals will be conducted through complaint trending and other post market safety surveillance activities.No further action is recommended at this time.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|